2009
Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study
Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM. Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study. Clinical Genitourinary Cancer 2009, 7: e58-e65. PMID: 19815483, DOI: 10.3816/cgc.2009.n.025.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaMulticenter phase I/II studyPhase I/II studyStage IV renal cell carcinomaPF-3512676II studyCell carcinomaAntitumor activityAdvanced metastatic renal cell carcinomaToll-like receptor 9 agonistMetastatic renal cell carcinomaAdvanced renal cell carcinomaLocal injection site reactionsPhase IGrade 3 fatigueGrade 4 AEsModest antitumor activityObjective response rateDose-limiting toxicityFlu-like symptomsInjection site reactionsReceptor 9 agonistSingle-agent treatmentPhase II expansionOpen label
2005
Renal cell carcinoma: Current status and future prospects
Drucker BJ. Renal cell carcinoma: Current status and future prospects. Cancer Treatment Reviews 2005, 31: 536-545. PMID: 16236454, DOI: 10.1016/j.ctrv.2005.07.009.Peer-Reviewed Original ResearchConceptsAdvanced renal cell carcinomaRenal cell carcinomaTotal nephrectomyLocalized Renal Cell CarcinomaStandard systemic treatmentSubset of patientsMost patientsSystemic treatmentCurative treatmentRadical nephrectomyPoor prognosisCell carcinomaUnderlying pathophysiologyStandard treatmentRenal tumorsInvasive treatmentNew agentsTumor growthNephrectomyPatientsEarly detectionMolecular pathwaysSurgeryTreatmentDiagnostic methods
2004
Phase II Trial of Bortezomib for Patients With Advanced Renal Cell Carcinoma
Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M, Motzer RJ. Phase II Trial of Bortezomib for Patients With Advanced Renal Cell Carcinoma. Journal Of Clinical Oncology 2004, 22: 3720-3725. PMID: 15365068, DOI: 10.1200/jco.2004.10.155.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaRenal cell carcinomaGrade 3 sensory neuropathyPartial responseSensory neuropathyCell carcinomaM2 groupAdvanced renal cell carcinomaToxicity of bortezomibPhase II trialAssessable patientsStable diseaseII trialInterferon alfaUnacceptable toxicityClinical responseCytokine therapyCombination therapyIntravenous administrationNovel agentsIndividual patientsDose reductionResponse durationHigh doseAntitumor effects
2003
Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma
Drucker B, Bacik J, Ginsberg M, Marion S, Russo P, Mazumdar M, Motzer R. Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma. Investigational New Drugs 2003, 21: 341-345. PMID: 14578682, DOI: 10.1023/a:1025472712456.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsCarcinoma, Renal CellFemaleGefitinibHumansKidney NeoplasmsMaleMiddle AgedQuinazolinesSurvival RateTreatment OutcomeConceptsRenal cell carcinomaAdvanced renal cell carcinomaPhase II trialII trialCell carcinomaMemorial Sloan Kettering Cancer Center databaseMetastatic renal cell carcinomaCancer Center databaseProgression of diseaseMonths of startEvaluable patientsMedian TTPPartial responseCell patientsDisease progressionPatientsTreatment efficacyCenter databaseZD1839Antitumor activityProgressionTrialsMonthsFurther studiesCarcinoma